A recent study by Tsinghua University’s School of Pharmaceutical Sciences has introduced a novel albumin-fluorometholone (Alb-FM) conjugate, capable of targeting pancreatic stellate cells (PSC) to modulate the tumor microenvironment, thereby enhancing the efficacy of gemcitabine in pancreatic cancer treatment. This marks a significant advancement in targeted drug delivery for difficult-to-treat cancers.

As a global leader in nanomedicine and drug delivery, Litchlab is at the forefront of albumin-based drug delivery systems, actively optimizing albumin nanoparticles (ANPs) and albumin-drug conjugates (ADCs) to improve targeted therapy for cancer, RNA-based drugs, and immunotherapy.

Litchlab’s Albumin-Based Drug Delivery Platform

Albumin, a natural carrier with high biocompatibility, prolonged circulation half-life, and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect, has emerged as a leading drug delivery vehicle. Litchlab’s platform is built on two key technologies:

1. Albumin Nanoparticle (ANP) Delivery System

Litchlab has developed stable, high-loading albumin nanoparticles (ANPs) to enhance drug solubility and targeted delivery:

· Precisely controlled nanoscale size (50-150 nm): Enhances tumor penetration and cellular uptake.

· Enhanced drug stability: Protects chemotherapeutic agents (e.g., paclitaxel, docetaxel) from rapid degradation.

· EPR effect enhancement: Facilitates selective accumulation at tumor sites while reducing systemic toxicity.

This platform is widely applied in small-molecule chemotherapy, RNA drug delivery, and immunotherapy.

2. Albumin-Drug Conjugate (ADC) Technology

Litchlab’s albumin-drug conjugation platform leverages chemical linkage and self-assembly strategies to improve drug stability and specificity:

· Controlled conjugation site selection: Optimizes drug release kinetics through precisely designed covalent bonds.

· Stimuli-responsive drug release: Ensures drug activation under tumor microenvironment conditions (e.g., pH-sensitive or enzyme-triggered release).

· Enhanced targeting potential: Combines albumin with monoclonal antibodies (mAbs) or aptamers for improved specificity.

Key Applications of Litchlab’s Albumin Delivery Technology

1. Targeted Cancer Therapy

· Alb-FM conjugates for pancreatic cancer therapy: Building on the Tsinghua study, Litchlab is optimizing albumin-corticosteroid conjugates to enhance tumor microenvironment modulation, improving gemcitabine efficacy.

· Alb-Paclitaxel (Albumin-Paclitaxel): Already widely used in breast, lung, and pancreatic cancer, Litchlab is enhancing next-generation formulations for higher tumor selectivity and reduced toxicity.

2. RNA Drug Delivery (mRNA / siRNA / ASO)

· Hybrid Albumin-LNP (ALB-LNP) system: Combines albumin with lipid nanoparticles (LNPs) to improve RNA stability and intracellular delivery.

· siRNA-Albumin Conjugates: Enables precise gene silencing and enhanced tissue targeting, particularly for liver and tumor-directed therapies.

3. Autoimmune & Inflammatory Disease Therapy

· Alb-Dexamethasone conjugates: Designed for rheumatoid arthritis and inflammatory bowel disease (IBD), ensuring targeted anti-inflammatory effects with reduced systemic side effects.

How Litchlab Accelerates Albumin-Based Drug Development?

Litchlab provides a full-spectrum solution from formulation development to GMP production, enabling rapid translation of novel albumin-based drug delivery systems into clinical applications:

Future Outlook: Litchlab Pioneering the Next Generation of Albumin Drug Delivery

The breakthrough in albumin-drug conjugates by Tsinghua University highlights the transformative potential of albumin-based drug delivery in tumor microenvironment modulation and targeted therapy.

Litchlab is driving innovation in nanomedicine and targeted therapy, leveraging advanced nanotechnology, conjugation chemistry, and RNA delivery strategies to revolutionize cancer therapy, RNA-based drugs, and chronic disease management.

Litchlab is committed to partnering with global pharmaceutical companies to accelerate the commercialization of next-generation albumin-based drug delivery technologie

For more information, please feel free to contact us at:  

E-Mail:RD2@Litchlab.com